Abstract: A capacitor component includes a body, including a dielectric layer and an internal electrode layer, and an external electrode disposed on the body and connected to the internal electrode layer. At least one hole is formed in the internal electrode layer, and a region, containing at least one selected from the group consisting of indium (In) and tin (Sn), is disposed in the hole. A method of manufacturing a capacitor component includes forming a dielectric green sheet, forming a conductive thin film, including a first conductive material and a second conductive material, on the dielectric green sheet, and sintering the conductive thin film to form an internal electrode layer. The internal electrode layer includes the first conductive material, and a region, including the second conductive material, is formed in the internal electrode layer.

Abstract: A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

Abstract: Provided are a method of screening for novel therapeutic targets to develop therapeutic agents for colon cancer, and prognostic biomarkers for colon cancer treatment which are screened using the same.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of an allergic disease comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient; a method for prevention or treatment of an allergic disease using the pharmaceutical composition; and a health functional food and a feed composition for improvement of an allergic disease. The composition provided in the present invention comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient can specifically inhibit the differentiation of Th2 cells and thus can be effectively used as a composition for prevention or treatment of an allergic disease.

Abstract: A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

Abstract: Provided are a method of screening for novel therapeutic targets to develop therapeutic agents for colon cancer, and prognostic biomarkers for colon cancer treatment which are screened using the same.

Abstract: The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.

Abstract: Rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (CCP), a rheumatoid arthritis diagnosis method using the CCP, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.

Abstract: The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

Abstract: The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.

Abstract: The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

Abstract: Rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (CCP), a rheumatoid arthritis diagnosis method using the CCP, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.

Abstract: Biological metabolites LysoPC (18:0), LysoPC (20:3), fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2) and fatty acid (22:6) according to the present disclosure allow for simple and accurate diagnosis of a cardiovascular disease since their level in the blood of a subject increases or decreases if the subject has a cardiovascular disease such as myocardial infarction or angina. In addition, whereas the existing biomarkers can diagnose only whether myocardial infarction occurs or not, the biological metabolites according to the present disclosure can diagnose not only myocardial infarction but also unstable angina occurring prior to the onset of myocardial infarction stage by stage.

Abstract: The present disclosure relates to stomach cancer diagnosis using tryptophan metabolism rate in one aspect, and it relates to an invention using change of tryptophan metabolism rate in a stomach cancer patient, which is different from a normal person.

Abstract: Provided are a composition of a diagnostic biomarker for stomach cancer and a method of diagnosing stomach cancer using the same. The composition of a diagnostic biomarker for stomach cancer and the method of diagnosing stomach cancer using the same may be useful to determine stomach cancer from a patient with suspected stomach cancer.

Abstract: Provided are a complex including a quantum dot layer-containing bead particle and an agent for detecting or analyzing a target material; a composition including the complex for detecting the target material or for diagnosing myocardial infarction-related disease; and a method of diagnosing myocardial infarction-related disease by using the complex.

Abstract: Biological metabolites LysoPC (18:0), LysoPC (20:3), fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2) and fatty acid (22:6) according to the present disclosure allow for simple and accurate diagnosis of a cardiovascular disease since their level in the blood of a subject increases or decreases if the subject has a cardiovascular disease such as myocardial infarction or angina. In addition, whereas the existing biomarkers can diagnose only whether myocardial infarction occurs or not, the biological metabolites according to the present disclosure can diagnose not only myocardial infarction but also unstable angina occurring prior to the onset of myocardial infarction stage by stage.

Abstract: The present disclosure relates to stomach cancer diagnosis using tryptophan metabolism rate in one aspect, and it relates to an invention using change of tryptophan metabolism rate in a stomach cancer patient, which is different from a normal person.

Abstract: Provided are compositions for diagnosing acute myocardial infarction including a preparation for measuring an amount of a substance P (SubP) or neuropeptide Y (NpY), kits for diagnosing acute myocardial infarction comprising the composition, and methods of diagnosing acute myocardial infarction based on the amount of the substance P or the neuropeptide Y.

Abstract: Provided are a composition of a diagnostic biomarker for stomach cancer and a method of diagnosing stomach cancer using the same. The composition of a diagnostic biomarker for stomach cancer and the method of diagnosing stomach cancer using the same may be useful to determine stomach cancer from a patient with suspected stomach cancer.